Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Status:
Recruiting
Trial end date:
2021-10-11
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of talazoparib in combination with
radiation therapy and to see how well they work in treating patients with gynecologic cancers
that have come back after previous treatment (recurrent). Talazoparib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses
high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination
with radiation therapy may work better in treating patients with gynecologic cancers.